PURE Bioscience Sets Q3 Results Conference Call to Review Progress of SDC-Based Antimicrobial Food Safety Solutions Strategy
- #PURE--PURE Bioscience, Inc. (OTCQB:
PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC)
antimicrobial, announced today that the Company will publish fiscal Q3
financial results shortly after the market closes, and host an investor
conference call on Thursday, June 8, 2017 at 1:30pm PDT (4:30pm EDT).
In addition to discussion of third fiscal quarter and nine-month 2017 results, PURE’s management will review the progress made to commercialize SDC as a food safety solution.
The Participant Dial-In Number for the conference call is 1-631-891-4304. Participants should dial in to the call at least five minutes before 1:30pm PDT (4:30pm EDT) on June 8, 2017. The call can also be accessed “live” online at http://public.viavid.com/index.php?id=123679.
A replay of the webcast will be available on the Company’s website (http://www.purebio.com/about/investor_relations). A replay of the conference call will be available by dialing 1-844-512-2921 (international participants dial 1-412-317-6671) starting June 8, 2017, at 7:30pm EDT through June 15, 2017 at 11:59 pm EDT. Please use PIN Number 10002719.
About PURE Bioscience, Inc.
PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena -- providing solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and it mitigates bacterial resistance. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.
Forward-looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from any forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s ability to receive required regulatory approvals for use of PURE Control in OLR poultry processing, including the required data from plant trials, on a timely basis, or at all; the Company’s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company's current and future products and services in the marketplace, including the Company’s ability to convert successful evaluations and tests into customer orders, the timing of customer testing and orders, customers continuing to place product orders as expected and to expand their use of the Company’s products throughout their operations; the ability of the Company to develop effective new products and to receive required regulatory approvals for such products, including the required data from plant trials; competitive factors; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the fiscal year ended July 31, 2016, its Form 10-Q for the first quarter ended October 31, 2016 and its Form 10-Q for the second quarter ended January 31, 2017. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
ContactsPURE Bioscience, Inc.
Hank Lambert, CEO
619-596-8600 ext.103
[email protected]
or
Bibicoff + MacInnis, Inc.
Terri MacInnis, VP of IR
818-379-8500
[email protected]
or
Redwood Investment Group
Tom Hemingway
714-978-4425
[email protected]
&source=" target="_blank" />
SAN DIEGO–(BUSINESS WIRE)–#PURE—PURE Bioscience, Inc. (OTCQB:
PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC)
antimicrobial, announced today that the Company will publish fiscal Q3
financial results shortly after the market closes, and host an investor
conference call on Thursday, June 8, 2017 at 1:30pm PDT (4:30pm EDT).
In addition to discussion of third fiscal quarter and nine-month 2017
results, PURE’s management will review the progress made to
commercialize SDC as a food safety solution.
The Participant Dial-In Number for the conference call is
1-631-891-4304. Participants should dial in to the call at least five
minutes before 1:30pm PDT (4:30pm EDT) on June 8, 2017. The call can
also be accessed “live” online at http://public.viavid.com/index.php?id=123679.
A replay of the webcast will be available on the Company’s website (http://www.purebio.com/about/investor_relations).
A replay of the conference call will be available by dialing
1-844-512-2921 (international participants dial 1-412-317-6671) starting
June 8, 2017, at 7:30pm EDT through June 15, 2017 at 11:59 pm EDT.
Please use PIN Number 10002719.
About PURE Bioscience, Inc.
PURE Bioscience, Inc. is focused on developing and commercializing our
proprietary antimicrobial products primarily in the food safety arena —
providing solutions to the health and environmental challenges of
pathogen and hygienic control. Our technology platform is based on
patented stabilized ionic silver, and our initial products contain
silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic
antimicrobial agent, which offers 24-hour residual protection and
formulates well with other compounds. As a platform technology, SDC is
distinguished from existing products in the marketplace because of its
superior efficacy, reduced toxicity and it mitigates bacterial
resistance. PURE is headquartered in El Cajon, California (San Diego
metropolitan area). Additional information on PURE is available at www.purebio.com.
Forward-looking Statements
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements as that term
is defined in the Private Securities Litigation Reform Act of 1995.
Forward-looking statements inherently involve risks and uncertainties
that could cause our actual results to differ materially from any
forward-looking statements. Factors that could cause or contribute to
such differences include, but are not limited to, the Company’s ability
to receive required regulatory approvals for use of PURE Control in OLR
poultry processing, including the required data from plant trials, on a
timely basis, or at all; the Company’s failure to implement or otherwise
achieve the benefits of its proposed business initiatives and plans;
acceptance of the Company’s current and future products and services in
the marketplace, including the Company’s ability to convert successful
evaluations and tests into customer orders, the timing of customer
testing and orders, customers continuing to place product orders as
expected and to expand their use of the Company’s products throughout
their operations; the ability of the Company to develop effective new
products and to receive required regulatory approvals for such products,
including the required data from plant trials; competitive factors;
dependence upon third-party vendors, including to manufacture its
products; and other risks detailed in the Company’s periodic report
filings with the Securities and Exchange Commission (the SEC), including
its Form 10-K for the fiscal year ended July 31, 2016, its Form 10-Q for
the first quarter ended October 31, 2016 and its Form 10-Q for the
second quarter ended January 31, 2017. You should not place undue
reliance on these forward-looking statements, which speak only as of the
date of this press release. By making these forward-looking statements,
the Company undertakes no obligation to update these statements for
revisions or changes after the date of this release.
Contacts
PURE Bioscience, Inc.
Hank Lambert, CEO
619-596-8600 ext.103
[email protected]
or
Bibicoff
+ MacInnis, Inc.
Terri MacInnis, VP of IR
818-379-8500
[email protected]
or
Redwood
Investment Group
Tom Hemingway
714-978-4425
[email protected]
